- Home
- AVK vs ARVN Comparison
AVK vs ARVN Comparison
Compare AVK & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVK
- ARVN
- Stock Information
- Founded
- AVK 2003
- ARVN 2015
- Country
- AVK United States
- ARVN United States
- Employees
- AVK N/A
- ARVN N/A
- Industry
- AVK Trusts Except Educational Religious and Charitable
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- AVK Finance
- ARVN Health Care
- Exchange
- AVK Nasdaq
- ARVN Nasdaq
- Market Cap
- AVK 571.7M
- ARVN 676.2M
- IPO Year
- AVK N/A
- ARVN 2018
- Fundamental
- Price
- AVK $12.63
- ARVN $10.58
- Analyst Decision
- AVK
- ARVN Buy
- Analyst Count
- AVK 0
- ARVN 23
- Target Price
- AVK N/A
- ARVN $17.75
- AVG Volume (30 Days)
- AVK 112.9K
- ARVN 2.6M
- Earning Date
- AVK 01-01-0001
- ARVN 11-05-2025
- Dividend Yield
- AVK 11.85%
- ARVN N/A
- EPS Growth
- AVK N/A
- ARVN N/A
- EPS
- AVK N/A
- ARVN N/A
- Revenue
- AVK N/A
- ARVN $312,300,000.00
- Revenue This Year
- AVK N/A
- ARVN N/A
- Revenue Next Year
- AVK N/A
- ARVN N/A
- P/E Ratio
- AVK N/A
- ARVN N/A
- Revenue Growth
- AVK N/A
- ARVN 93.86
- 52 Week Low
- AVK $9.24
- ARVN $5.90
- 52 Week High
- AVK $12.16
- ARVN $28.76
- Technical
- Relative Strength Index (RSI)
- AVK 42.81
- ARVN 67.95
- Support Level
- AVK $12.83
- ARVN $9.27
- Resistance Level
- AVK $12.90
- ARVN $10.18
- Average True Range (ATR)
- AVK 0.14
- ARVN 0.44
- MACD
- AVK -0.02
- ARVN 0.02
- Stochastic Oscillator
- AVK 27.92
- ARVN 100.00
About AVK Advent Convertible and Income Fund
Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.